<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278758</url>
  </required_header>
  <id_info>
    <org_study_id>CASA404A2109</org_study_id>
    <secondary_id>EudraCT 2009-017159-88</secondary_id>
    <nct_id>NCT01278758</nct_id>
  </id_info>
  <brief_title>A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function</brief_title>
  <official_title>A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and pharmacokinetics of ASA404 in&#xD;
      patients with refractory or relapsed metastatic cancer with impaired renal function and with&#xD;
      normal renal function. It is very possible that patients with renal impairment will show&#xD;
      differences in renal excretion of parent ASA404 and its metabolites, warranting a study that&#xD;
      leads to a better pharmacokinetic assesssment in this population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2010</start_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pK of a single intravenous dose of ASA404 1200 and 1800 mg/m2 monotherapy in adult cancer patients with impaired renal function compared to matching patients with normal renal function</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of a single i.v. dose of ASA 1200 and 1800 mg/m2 +chemotherapy (doctaxel or paclitaxel + carboplatin) in adult cancer patients with impaired renal function compared to matching patients with normal renal function</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of ASA404 in adult cancer patients with impaired renal function compared to matching patients with normal renal function</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of ASA404 1200 or 1800 mg/m2 in combination with chemotherapy (docetaxel or paclitaxel + carboplatin)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate ASA404 pharmacokinetic parameters including AUC (0-t last),), AUC (0-inf)), T ((Â½)), CL, V(Z), Cmax, and Tmax</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate renal clearance (CLR) of ASA404.</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>ASA404 + standard therpy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA404, DMXAA or DXAA</intervention_name>
    <arm_group_label>ASA404 + standard therpy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients having histologically-proven solid tumors, who are either refractory to&#xD;
             standard chemotherapy;&#xD;
&#xD;
          -  Patients whom chemotherapy with an investigaional agent in combination with docetaxel,&#xD;
             or paclitaxel + carboplatin is appropriate;&#xD;
&#xD;
          -  Creatinine clearance according to Cockcroft-Gault formula : Normal &gt; 80 mL/min, Mild&#xD;
             50-80 mL/min, Moderate 30-&lt;50 mL/min;&#xD;
&#xD;
          -  A minimum of 4 weeks must have elapsed since the last treatment with other cancer&#xD;
             therapies;&#xD;
&#xD;
          -  Potassium, calcium, magnesium and phosphorus values within the normal range;&#xD;
&#xD;
          -  Body Mass Index (BMI) must be within the range of 18 and 30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients having CNS metastases, must have a CT or MRI of the brain performed to rule&#xD;
             out CNS metastases;&#xD;
&#xD;
          -  Patients with leptomeningeal disease metastases;&#xD;
&#xD;
          -  Radiotherapy &lt;/- weeks prior to starting study drug;&#xD;
&#xD;
          -  Major surgery &lt;/ 4 weeks prior to the start of study;&#xD;
&#xD;
          -  Administration of CYP1A2 and CYP3A4/5 enzyme inducing or inhibiting drugs within 14&#xD;
             days prior to starting study drug;&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Investigative Site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center, Hematology/Oncology Dept.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology /Oncology Associates</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joseph Ford Cancer Center/Clinical Trials Office, Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5426</url>
    <description>Results for CASA404A2109 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>January 16, 2011</study_first_submitted>
  <study_first_submitted_qc>January 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2011</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced or metastatic cancer,</keyword>
  <keyword>refractory,</keyword>
  <keyword>core phase,</keyword>
  <keyword>extension phase,</keyword>
  <keyword>dose escalation,</keyword>
  <keyword>standard chemotherapy,</keyword>
  <keyword>doctaxel,</keyword>
  <keyword>paclitaxel,</keyword>
  <keyword>carboplatin,</keyword>
  <keyword>safety,</keyword>
  <keyword>tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vadimezan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

